Platelet-activating Factor Receptor (PAFR) Antagonist

Platelet-activating Factor Receptor (PAFR) Antagonists (25):

Cat. No.	Product Name	Effect	Purity

HY-N0784

Ginkgolide B	Antagonist	99.96%
Ginkgolide B (BN-52021), a terpene lactone, is a potent platelet activating factor antagonist. Ginkgolide B protects endothelial cells via the activation of PXR from injuries induced by xeno- and endobiotics. Ginkgolide B can pass through the brain-blood barrier. Ginkgolide B has anti-oxidant, anti-inflammatory, anti-tumor, and anti-apoptotic activity. Ginkgolide B has marked neuroprotective effects against ischemia-induced impairments.

HY-N12995

α-Bulnesene	Antagonist
α-Bulnesene is a novel PAF receptor antagonist with the IC₅₀ of 17.62 μM. α-Bulnesene can be isolated from Pogostemon cablin. α-Bulnesene shows inhibitory effect on platelet-activating factor and arachidonic acid induced rabbit platelet aggregation.

HY-19126

CL-184005	Antagonist
CL-184005 is an antagonist for platelet-activating factor (PAF), that inhibits the PAF-induced platelet aggregation with IC₅₀ of 600 nM and 510 nM, in human and rabbit platelet-rich plasma. CL-184005 protects the rats from endotoxin-induced gastrointestinal damage and hypotension. CL-184005 exhibits potential attenuating Gram-negative bacterial sepsis.

HY-163101

CP-96021	Antagonist
CP-96021 is a potent and orally available leukotriene D₄ (LTD₄ K_i=34 μM) / platelet activating factor (PAF K_i=37 μM) receptor antagonist. CP-96021 has antagonist capable of simultaneously targeting two different inflammatory mediators, LTD₄ and PAF. CP-96021 shows high specificity for α1, α2, β, dopamine-2, adenosine 1, 5-HT1, H1, muscarine, μ opioid, and GABA receptors, all expressing IC₅₀ values greater than 10 μM. CP-96021 can be used to study the pathogenesis of many inflammatory diseases such as asthma.

HY-N10663

Kadsurenone	Antagonist	≥99.0%

HY-N3436

Kadsurin A	Antagonist
Kadsurin A is a new lignan can be isolated from Piper futokadsura. Kadsurin A is a platelet activating factor (PAF) receptor antagonist that weakly inhibits the binding of PAF to its receptor.

HY-132190

Hexanolamino PAF C-16	Antagonist
Hexanolamino PAF C-16 (1-O-hexadecyl-2-acetyl-sn-glycero-3-phospho (N,N,N trimethyl) hexanolamine) is a Platelet-activating Factor Receptor (PAFR) Modulator with partial agonist activity. Hexanolamino PAF C-16 induces platelet aggregation and macrophage production but fails to increase [Ca2+]i in platelets, suggesting that PAF receptors may interact with PAF receptors through Ca²⁺-dependent and -independent pathways. Related to platelet aggregation.

HY-121377

Epiyangambin	Antagonist
Epiyangambin is a competitive platelet activating factor receptor (PAF) antagonist that dose-dependently inhibits PAF-induced platelet aggregation. Epiyangambin also inhibits the growth of human colon cancer cells (SW480 cells).

HY-116120

N-Acetyldesloratadine	Antagonist	99.93%
N-Acetyldesloratadine (SCH-37370) is a potent, orally active dual antagonist of platelet-activating factor (PAF) and histamine. N-Acetyldesloratadine inhibits PAF-induced aggregation of human platelets, with an IC₅₀ of 0.6 µM.

HY-W700638A

Benafentrine maleate	Antagonist
Benafentrine maleate is a platelet activating factor receptor (PAFR) antagonist and a PDE 4 inhibitor.

HY-106837

Israpafant	Antagonist
Israpafant (Y-24180) is a potent, selective and long-acting platelet activation factor (PAF) receptor antagonist with IC₅₀s of 0.84 nM and 3.84 nM against PAF-induced human and rabbit platelet aggregation, respectively. Israpafant stimulates both extracellular Ca²⁺ influx and intracellular Ca²⁺ release in prostate cancer cells. Israpafant suppresses the allergic cutaneous reactions including eosinophilia, cytokine production, edema and erythema in mice.

HY-101654

Rocepafant	Antagonist
Rocepafant (BN 50730) is a specific platelet activating factor (PAF) antagonist. Rocepafant can be used in rheumatoid arthritis and nervous system research.

HY-106833A

SDZ-62-434	Antagonist
SDZ-62-434 is a platelet-activating factor (PAF) antagonist. SDZ-62-434 has antiproliferative activity in human solid and haematological malignancies.

HY-123399

Ro 19-1400	Antagonist
Ro 19-1400 is a platelet-activating factor antagonist that directly inhibits immunoglobulin E-dependent mediator release.

HY-124887

L 651142	Antagonist
L 651142 is a weak platelet activating factor (PAF) receptor antagonist. L 651142 inhibits the binding of [³H]PAF to rabbit platelet, human platelet or human lung membranes with K_is of 0.839 μM, 1.82 μM, 3.64 μM, respectively.

HY-N7343

Pregomisin	Antagonist
Pregomisin is a natural compound isolated from the fruits of Schizandra chinensis Baill. Pregomisin showed PAF antagonistic activity and the IC₅₀ values were 48 μM.

HY-123505

Dersalazine sodium	Antagonist
Dersalazine (sodium) is a platelet-activating factor (PAF) antagonist. Dersalazine (sodium) can exert intestinal anti-inflammatory activity in rodent colitis models by downregulating IL-17 expression.

HY-122126

BN 52111	Antagonist
BN 52111 is a potent platelet-activating factor (PAF) receptor antagonist.

HY-133003

L662,025	Antagonist
L662,025 is a specific, photolabile and irreversible Platelet-activating factor (PAF-receptor) antagonist, with IC₅₀ values of 5.6 μM (platelet aggregation) and 1 μM (receptor binding), respectively.

HY-119035

R-75317	Antagonist
R-75317 is a specific platelet-activating factor (PAF) antagonist. R-75317 can prevent the decline in creatinine clearance (Ccr) in a rat model of glomerulonephritis induced by the injection of antibodies extracted from rabbits against rat glomerular basement membrane (GBM) antigens, delay the onset of proteinuria, and improve glomerular hypertrophy, mesangial matrix proliferation, and interstitial fibrosis. R-75317 may be useful in the study of glomerulonephritis.

Name
Email *

	Sorry, but the email address you supplied was invalid.